Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.
|Videos|June 30, 2022
Subcutaneous Epcoritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study
Author(s)Tycel J. Phillips, MD
Dr. Tycel Phillips reviews pivotal dose-expansion results from the EPCORE NHL-1 trial on epcoritamab in patients with relapsed or refractory large B-cell lymphoma (LBCL).
Advertisement
Advertisement
Related to this article
Nirav N. Shah, MD, MSHP, discusses bexobrutideg and what the BTK degrader could bring to chronic lymphocytic leukemia management.
Promising data for zenocutuzumab in patients with advanced NRG1-positive cholangiocarcinoma were shown according to researchers at Dana-Farber.
OncLive spoke with expert investigators to gather insights on the role of AI in cancer care, including oncologic surgery and drug development.
Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.
The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
2
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
3
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
4
FDA Issues CRL to Orviglance for Liver Metastasis Imaging in Patients With Severe Kidney Impairment
5